Table 2 Clinical characteristics of GC patients according to GLT8D2 expression
Characteristic | Low expression of GLT8D2 | High expression of GLT8D2 | P |
|---|---|---|---|
n | 187 | 188 | Â |
Gender, n (%) | Â | Â | 0.617 |
Female | 64 (17.1%) | 70 (18.7%) | Â |
Male | 123 (32.8%) | 118 (31.5%) | Â |
T stage, n (%) |  |  | < 0.001 |
T1 | 18 (4.9%) | 1 (0.3%) | Â |
T2 | 43 (11.7%) | 37 (10.1%) | Â |
T3 | 84 (22.9%) | 84 (22.9%) | Â |
T4 | 42 (11.4%) | 58 (15.8%) | Â |
N stage, n (%) | Â | Â | 0.473 |
N0 | 53 (14.8%) | 58 (16.2%) | Â |
N1 | 51 (14.3%) | 46 (12.9%) | Â |
N2 | 43 (12%) | 32 (9%) | Â |
N3 | 34 (9.5%) | 40 (11.2%) | Â |
M stage, n (%) | Â | Â | 1.000 |
M0 | 167 (47%) | 163 (45.9%) | Â |
M1 | 13 (3.7%) | 12 (3.4%) | Â |
Pathologic stage, n (%) | Â | Â | 0.073 |
Stage I | 35 (9.9%) | 18 (5.1%) | Â |
Stage II | 49 (13.9%) | 62 (17.6%) | Â |
Stage III | 75 (21.3%) | 75 (21.3%) | Â |
Stage IV | 20 (5.7%) | 18 (5.1%) | Â |
H. pylori infection, n (%) | Â | Â | 0.302 |
No | 95 (58.3%) | 50 (30.7%) | Â |
Yes | 9 (5.5%) | 9 (5.5%) | Â |
Histologic grade, n (%) | Â | Â | 0.011 |
G1 | 5 (1.4%) | 5 (1.4%) | Â |
G2 | 82 (22.4%) | 55 (15%) | Â |
G3 | 96 (26.2%) | 123 (33.6%) | Â |
Residual tumor, n (%) | Â | Â | 0.623 |
R0 | 157 (47.7%) | 141 (42.9%) | Â |
R1 | 6 (1.8%) | 9 (2.7%) | Â |
R2 | 8 (2.4%) | 8 (2.4%) | Â |
OS event, n (%) | Â | Â | 0.038 |
Alive | 124 (33.1%) | 104 (27.7%) | Â |
Dead | 63 (16.8%) | 84 (22.4%) | Â |
DSS event, n (%) | Â | Â | 0.393 |
Alive | 137 (38.7%) | 126 (35.6%) | Â |
Dead | 42 (11.9%) | 49 (13.8%) | Â |
Age, n (%) | Â | Â | 0.553 |
<=65 | 78 (21%) | 86 (23.2%) | Â |
> 65 | 106 (28.6%) | 101 (27.2%) |  |